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ABSTRACT Interleukin-13 (IL-13) is a pleiotropic cytokine that controls growth, differentiation, and apoptosis of immune and
tumor cells. To understand the mechanisms of interaction between IL-13 and IL-13 receptors (IL-13R), and the role of the IL-2
receptor common  chain (c) in IL-13 binding and processing, we have examined IL-13 binding kinetics, dissociation/
shedding, and internalization in renal cell carcinoma (RCC) cell lines. We observed a new phenomena in that the apparent rate
of association, but not the dissociation, was strongly related to IL-13 concentration. We also observed cooperativity
phenomena in IL-13 and IL-13R interaction in control RCC (MLneo) cells, but not in cells transfected with c chain (MLc). The
number of IL-13 binding sites, the effective rate of ligand association, and the dissociation rate constants were reduced in
c-transfected cells compared to control RCC cells. Two forms of IL-13R were detected in these cell lines, which differed in
the kinetics of endocytosis and dissociation/exocytosis. Only a small fraction of bound receptors (14–24%) was rapidly
internalized and the same fraction of the ligand-receptor complexes was shed and/or dissociated. The expression of c chain
did not change any of these processes. A two independent high-affinity and moderate-affinity receptor model fit the kinetic
observations in c-transfected cells. However, in control cells, the binding kinetics were more complicated. A mathematical
model that fit a set of kinetic and steady state data in control cells was selected from a set of possible models. This best-fit
model predicts that 1) two different IL-13R are expressed on the cell membrane, 2) a minor fraction of IL-13R exist as
microclusters (homodimers and/or heterodimers) without exogenous IL-13, 3) high morphological complexity of the c-
negative control cell membrane affects the cooperativity phenomena of IL-13 binding, and 4) a large number of co-receptor
molecules is present, which helps keep the ligand on the cell surface for a long period of time after fast IL-13 binding and
provides a negative control for ligand binding via production of the high affinity inhibitor bound to IL-13. Our data demonstrate
that c exerts dramatic changes in the kinetic mechanisms of IL-13 binding.
INTRODUCTION
Human interleukin (IL)-13 is a 12-kDa pleiotropic cytokine
that is expressed in activated Th1 and Th2 lymphocytes
(Minty et al., 1993; McKenzie et al., 1993), stimulated
keratinocytes, activated mast cells and transformed B lym-
phocytes (Minty et al., 1993; McKenzie et al., 1993; de
Waal, 1993). It inhibits proliferative activity of normal B
cells and their precursors, B-CLL cells, and it protects
B-CLL cells from spontaneous apoptosis (Chaouchi et al.,
1996). A number of biological effects recently reported for
IL-13 were previously observed for IL-4. But, in contrast to
IL-4, IL-13 has not been shown to modulate growth char-
acteristics of T lymphocytes (Zurawski and de Vries, 1994).
The effects of IL-13 are mediated by specific plasma
membrane receptors (R). We have recently reported that a
variety of human solid tumor cells express intermediate to
high affinity IL-13R* and that their interaction with IL-13
inhibits growth of some human RCC cells (Obiri et al.
1996a). We proposed that IL-13R exists in three or four
different forms in various cell types (Obiri et al., 1997).
Type I IL-13R expressed in human RCC cells appear to be
composed of a homodimer of p65-70 proteins [termed IL-
13R1 (or ) and 2 (or )]. In type II IL-13R, IL-13R1
forms a heterodimer with IL-4R p140 chain termed IL-4R.
In types III and IV IL-13R, IL-13 binds IL-13R1 and
IL-4R subunits and IL-2R-chain (c) may (type III) or
may not (type IV) modulate IL-13 binding (Obiri et al.,
1996b).
Although, the structure and biological properties of IL-
13R are being vigorously investigated, the kinetics of IL-13
binding, dissociation, internalization, shedding, recycling,
and degradation have not been studied. Knowledge of the
biophysical and biochemical mechanisms of these processes
is necessary for an understanding of the mechanisms of
intracellular signaling and biological response of target
cells. Fitting mathematical models that correspond to the
kinetics of these processes may result in better understand-
ing of the biochemical and biophysical properties of IL-
13R, similar to IL-2R, IL-4R (Goldstein et al., 1992;
Kuznetsov and Borisova, 1995a; Borisova and Kuznetsov,
1996) and other receptor systems (Gex-Fabry and DeLisi,
1984; Bajzer et al., 1989; Wofsy et al., 1992; Rovati et al.,
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1996). In this manuscript, we have studied IL-13 binding
kinetics on two RCC cell lines (HL-RCC and ML-RCC) and
evaluated the influence of c gene expression on IL-13 and
IL-13R interaction in ML-RCC cells transfected with c
cDNA. The kinetics of binding, dissociation, shedding of
IL-13R, and ligand-induced receptor-mediated endocytosis
of ligand has been investigated. We used mathematical
models to analyze the kinetics of IL-13 binding to its
receptors.
MATERIALS AND METHODS
Cytokines and reagents
Recombinant human IL-13 was expressed in Escherichia coli and purified
as described (Debinski et al., 1995).
Cells
The RCC cell lines ML-RCC and HL-RCC were established in our labo-
ratory from primary surgical tissues and were maintained in HEPES
buffered DMEM with high glucose supplemented with glutamine plus 10%
fetal bovine serum (FBS) and antibiotics (penicillin, 100 U/mL and strep-
tomycin, 100 g/mL) (Obiri et al., 1993). The c-cDNA, along with
neomycin transferase cDNA, was transfected into ML-RCC cells as pre-
viously described (Puri et al., 1996b).
Iodination of IL-13
IL-13 was labeled with 125I (Amersham Research Products, Arlington
Heights, IL) using IODO-GEN reagent (Pierce, Rockford, IL) according to
the manufacturer’s instructions. The specific activity of the radiolabeled
IL-13 was estimated to range from 80 to 120 Ci/g protein (Obiri et al.,
1995).
Kinetics of IL-13 binding and dissociation
All binding and dissociation experiments were performed at 4°C to prevent
receptor-mediated IL-13 internalization. The association kinetic studies
were performed by incubating 0.5  106 or 1.0  106 cells with various
concentrations (10–500 pM) of 125I-IL-13 in 120 L binding buffer (RPMI
1640 containing 0.2% human serum albumin and 10 mM HEPES) for 3
min to 18 h at 4°C. Nonspecific binding was determined for each 125I-
IL-13 concentration and each time point by co-incubation with 50 nM
unlabeled IL-13. In some cases, nonspecific binding was established by
determining total 125I-IL-13 bound to cells after a short incubation (3–6
min) with radio-labeled IL-13. Both techniques gave similar results and the
average value of these data was used as the nonspecific binding. The
specific fraction of bound ligand was calculated by
zti/y0
cpmi cpmn
cpmtot cpmn
, (1)
where y0, and z are the initial concentration of the radio-labeled ligand in
the medium and the concentration of specifically bound ligand at time ti,
respectively; z(ti)/y0 is the specific bound fraction of
125I-IL-13 at time ti,
i 1, 2, 3, . . . , and cpmi, cpmtot, cpmn represent cpm for bound, total, and
nonspecifically bound 125I-IL-13.
Cell-bound 125I-IL-13 was separated from unbound ligand by centrifu-
gation through a cushion of phthalate oils (Obiri et al., 1995). Radioactivity
in the cell pellets and supernatants was counted in a gamma-counter.
For dissociation kinetic assays, aliquots were taken after 4–6 h of
incubation at 4°C, which allowed time to attain a state of equilibrium at the
concentration of ligand used. Cells were then centrifuged at 1500  g for
5 min to remove free radioactive material, washed twice with cold PBS and
resuspended to the initial volume with binding buffer containing 50 nM
unlabeled IL-13. At different time intervals, bound and free ligand was
measured as described above.
Competitive binding assays at 4°C
Two types of competitive binding experiments were performed. In the first
set of experiments, the binding of a single concentration of labeled IL-13
in the presence of various concentrations of unlabeled IL-13 (from 0 to 200
nM) at 4°C was measured at fixed time points. In the second set of
experiments, the binding of various concentrations of labeled IL-13 and a
single concentration of unlabeled ligand was determined at various times
from 2 min to 14 h.
Internalization assay
The c negative control (MLneo) or c transfected (MLc) RCC cells or
HL-RCC cells were incubated in binding buffer containing 0.2 nM chlo-
roquine at 37°C for 5 min to prevent degradation of internalized IL-13
(Obiri and Puri, 1994). Cells were then washed and 2.5 106 cells of each
type were incubated with 0.2 or 0.3 nM 125I-IL-13 at 4°C for 4.5 h, after
which unbound ligand was washed away with PBS. The cell pellets were
suspended in binding buffer and then quickly brought to 37°C. At various
time intervals, two duplicate sets of 50 L aliquots were taken. One set was
incubated with 100 L glycine buffer (25 mM glycine, 125 mM NaCl,
final pH  2.0) at 4°C for 10 min. The suspension was then centrifuged
through a mixture of phthalate oils and the radioactivity in the cell pellet
(acid resistant or internalized (Cin) and in the supernatant (surface bound
dissociated, Cs  Cout) was measured with a gamma counter. The other set
of 50 L aliquots was directly centrifuged through phthalate oils and the
radioactivity measured in the supernatant was used for dissociated 125I-
IL-13 values (Cout). Surface bound
125I-IL-13 was determined by subtract-
ing internalized 125I-IL-13 values from surface bound  internalized
values. Internalized, dissociated, and surface bound radioactivity values
were added to obtain total bound value cpm.
Fractions of specific surface bound (Cs), internalized (Cin) and shed/
dissociated (Cout) ligand were calculated by
Cs a/a b c c0/c d,
Cin c c0/c d,
Cout b/a b,
where a  bound  internalized, b  dissociated ligand, c  internalized
ligand, d  bound  dissociated ligand, a  b is the total in experiment
1 (without glycine treatment); c  d is the total in experiment 2 (after
glycine treatment); c0 is the nonspecific internalized ligand. The kinetic
parameters for the internalization experiments were estimated by the two
independent binding sites model (Kuznetsov, 1990).
Analysis of association kinetics by one binding
site model
Kinetic binding of IL-13 was analyzed by one binding site model. Accord-
ing to this model,
x yº
k1
k1
z, (2)
where x, y, and z are the concentrations of unbound receptor, unbound
ligand, and their bound pairs [z (x y)], respectively, and k1, k1 are the
association and dissociation rate constants for reaction 2, respectively. For
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fitting the model to kinetic data, we used the exact solution of the differ-
ential equation which corresponds to the kinetic scheme 2 as described by
Kuznetsov (1996).
A fractal analysis of IL-13 binding kinetics
The model of diffusion of a ligand in homogeneous solution to a fractal
dimension surface where it forms a ligand-receptor complex was described
by Havlin (1989). For analysis of binding of macromolecules to membrane
receptors, this model can be rewritten as
zt
y0
 NcR0k1  t3Df/2 at t	 tct1/2 at t
 tc, (3)
where z is the concentrations of bound ligand-receptor pairs, y0 is the initial
concentration of the ligand in the medium far from the cell surface, Nc is
the concentration of cells, and R0 is the average number of receptor
molecules per cell (R0  x0/Nc), where x0 is the initial concentration of
receptor. k1 is the binding rate of ligand to receptor, Df is the fractal
dimension (complexity) of the surface, tc is the characteristic time when
regular diffusion of ligand to the cell surface dominates. The effective
binding rate by this model is f k1R0Nc. Eq. 3 indicates that, in the fractal
kinetic reaction, the concentration of ligand-receptor complex on cell
surfaces z(t) is proportional to tp, where p  (3  Df)/2 during the early
reaction period (t 	 tc), and p  1⁄2 outside (Havlin, 1989).
Analysis of kinetic association data by a two
independent binding site model
Our kinetic experiments were also analyzed using the kinetic scheme,
x1 yº
k1
k1
z1, x2 yº
k2
k2
z2 , (4)
where y, x1, x2 are the concentrations of the free ligand and their two forms
of independent receptors, respectively, and z1, z2 are the concentrations of
ligand-receptor pairs. The system of ordinary differential equation corre-
sponding to this kinetic scheme was used to evaluate the rate constants of
binding (k1, k2) and of dissociation (k1, k2) by curve-fitting.
Analysis of kinetic dissociation data
Dissociation data were analyzed using both the one receptor and two
independent receptor models. For the first model, the fraction of bound
ligand in time was described by
zt/z expk1t, (5)
where t is time in the dissociation assay,  is binding time, t 
 ; z() is
ligand bound to the receptor after binding time ; and k1 is the dissoci-
ation rate constant.
For the two independent receptor model, the time course of dissociation
was described with the two-exponential equation,
Bt ztott/ztot
 1 dexpk1t dexpk2t, (6)
where ztot is the sum concentration of the fast (z1) and slow (z2) receptors,
which differed with the rate of ligand dissociation, t is the current time of
dissociation, and  is the time of IL-13 binding on the cells after which the
dissociation experiment was started. ztot(t)  z1(t)  z2(t) is the concen-
tration of ligand bound to the slow (z1) and fast (z2) species at time t 
 ,
d()  z2()/ztot(). k1, k2 are the dissociation rates observed for each
species. Other parameters are the same as defined above.
Mathematical modeling for
internalization kinetics
Two simple mathematical models for processing kinetics (Kuznetsov and
Borisova, 1995a) were fit to the experimental data of the internalization
assay. For the first model, we presumed that a single IL-13–IL-13R
complex is formed and that it follows a single pathway for internalization,
dissociation, and shedding. For the second model, we assumed that two
independent IL-13–IL-13R complexes are formed, each of them having a
separate pathway of processing after ligand binding. Both models assume
that a concentration of unbound ligand is negligibly low. For the second
model, the following differential equations were used:
dzft
dt
1 inzf,
dzst
dt
2 inzs , (7)
dzint
dt
 inzf inzs,
dzoutt
dt
 1zf 2zs ,
where zf, zs are the type 1 and 2 ligand-receptor complex (LRCs) on the cell
surface, and zin, zout are the internalized and shed/dissociated LRCs, re-
spectively. Initial conditions (at t0  ) are defined as zf ()  zf0, zs () 
zs0, zin ()  zout ()  0; 1, 2 are the constant rates for shedding/
dissociation of the ligand/receptor type 1 complexes and ligand/receptor
type 2 complexes, respectively. in, in are the constant rates for internal-
ization of the ligand/receptor type 1 complexes and ligand/receptor type 2
complexes, respectively. Five parameters, f0(f0  zf0/(zf0  zs0), i (i  1,
2), in, in were estimated by fitting the model, Eq. 7, to the internalization
assay data by the method described in Kuznetsov (1990).
Proliferation assay
MLneo and MLc-transfected RCC cells were harvested, washed, and
resuspended in culture medium and 3.5  104 cells were plated in 10-cm2
tissue culture-treated Petri dishes (Falcon, Dickinson, Lakeridge, NJ) with
culture medium and cultured for different periods of time at 37°C in a 5%
CO2 environment. After 52, 72, 96, 124, 144, and 240 h of incubation, a
number of live cells was determined in duplicate dishes for each cell line
by harvesting the cells with versene, washing them, and resuspending to
0.25–0.5 mL for direct cell counts using a hemacytometer.
Simulation procedure
Simulations based on the nonlinear ordinary differential equations (stiff
method) corresponding to the models presented in this paper were per-
formed using MLAB modeling system (Civilized Software, Inc.; www.-
civilized.com).
Procedures for fitting of nonlinear
kinetic systems
For estimating parameters of the models, we used both the direct nonpara-
metric weighted global optimization method (Kuznetsov et al., 1993) and
the curve-fitting facilities of the MLAB mathematical and statistical mod-
eling system (Knott, 1996). A goodness-of-fit analysis of the models was
applied for data from association, dissociation, and displacement assays as
separate sets of data and pooled together. To get more accurate and robust
estimates of parameters, we used a cross-validation procedure for param-
eter estimation (V. A. Kuznetsov and G. D. Knott, in preparation). In this
approach, each experimental curve, in turn, was eliminated from the fitting
procedure. Then, the set of the best parameters was evaluated by fitting the
other experimental curves, and these parameter estimates were used to
calculate the sum of squared deviations of the predicted kinetic curve
points from the excluded experimental points. The reciprocals of these
sums were used as the weights of the set of evaluated parameters. Wil-
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coxon two-sample signed-rank testing and the method of Durbin and
Watson for testing the null hypothesis of serial independence of residuals
in the least squares analysis against the existence of positive or negative
correlation were applied.
RESULTS
Kinetic binding of 125I-IL-13 and dissociation
kinetics at 4°C
As shown in Fig. 1 A, the binding of radiolabeled IL-13 to
control MLneo c-negative cells reached steady state after
1 h, and persisted for up to 10 h. Similar forms of this
kinetic curve were observed when 50 nM unlabeled IL-13
was added in the reaction mixture (open circles, Fig. 1 A).
The level of specific IL-13 binding was reduced in c-
transfected cells compared to control cells (Fig. 1 B). In
addition, the apparent rate of binding in c-transfected cells
was slower compared to control cells. Furthermore, the
steady-state level of binding was reached between 4 and
5.5 h of incubation, compared to 1 h in control MLneo cells
(Fig. 1 B). The fraction of bound 125I-IL-13 to MI RCC
cells was much smaller than in control c-negative cells
(Fig. 1 A and C).
The rate of dissociation of a small fraction (10–20%) of
bound ligand was rapid in the initial phase (up to 10–20
min), but this was followed by a very slow phase in all RCC
cell lines (Fig. 1 D, E, and F). Such a slow dissociation rate
is unusual for cytokine receptors: most of them have half-
lives of 1–30 min. The calculated half-life, t1/2, of the
slow-dissociated ligand on HL, MLneo, and ML RCC cells
FIGURE 1 Time-dependent binding and
dissociation of 125I-IL-13 in RCC cells.
0.5 106 control MLneo (A), c-transfected
RCC cells (B) were incubated with 200 pM
125I-IL-13 and 1  106 HL-RCC cells (C)
were incubated with 100 pM 125I-IL-13 at
4°C with and without 50 nM of unlabeled
IL-13 for indicated period of time. Cell-
bound and free ligand were measured as
described in Materials and Methods. Black
circles, mean values of two determinations
in a direct binding assay; open circles,
mean values in a displacement binding as-
say. MLneo 10
6 (D) and MLc-transfected
(E) RCC cells were incubated with 200 pM
125I-IL-13 and 106 HL (F) RCC cells incu-
bated with 300 pM for 5 h at 4°C, washed
from unbound radiolabeled ligand and cells
were used for dissociation assays. Unla-
beled IL-13 100 pM was added immedi-
ately after washing the cells to prevent re-
binding of radiolabeled ligand. Data for
dissociation curves were corrected for non-
specific dissociation. The SDs for experi-
mental points were not larger than the size
of symbols presented on the figure. Asso-
ciation and dissociation assays were per-
formed in the same session. Data for ML-
and HL-RCC cell lines were obtained in
separate experiments. By trypan blue stain-
ing, 85–90% cells were alive in binding
buffer after 12 h incubation at 4°C. Exper-
iments were repeated two times with simi-
lar results.
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was 13.3  1 h, 27  3 h and 43  4 h, (mean  SD),
respectively. These results indicate that IL-13 binding and
dissociation at 4°C in c-transfected RCC cells is slower
than control cells.
Dissociation kinetics after binding of different
concentrations of IL-13 at 4°C
To determine whether dissociation kinetics vary with dif-
ferent concentration of bound 125I-IL-13, we measured the
rate of dissociation after preincubation of ML-RCC cells
with various concentrations of 125I-IL-13 for 3.5–5 h. As
shown in Fig. 2 A–C, in control MLneo RCC cells,
125I-
IL-13 dissociation kinetics did not vary with different
amounts of bound 125I-IL-13. The effective rate of the slow
phase of dissociation, k1, was 0.023 h
1, 0.017 h1, 0.025
h1, and 0.027 h1 at 15, 70, 200, and 500 pM of 125I-IL-
13, respectively. Similar results were obtained in c-trans-
fected cells (Fig. 2 D–F). The effective dissociation rates at
15, 150, 200, and 300 pM 125I-IL-13 were 0.014 h1, 0.016
h1, 0.017 h1, and 0.018 h1, respectively. Thus, the rate
of the slow phase of IL-13 dissociation from its receptor did
not depend on the amount of bound ligand; however, trans-
fection of c chain reduced this rate by 1.6 times (p	 0.05).
125I-IL-13 binding in the presence of different
concentrations of 125IL-13 at 4°C
It has been reported for several ligand-receptor systems that
the effective binding rate varies with the concentration of
ligand (Park et al., 1987; Sadana and Beelaram, 1996b;
Franco et al., 1996). We, therefore, examined whether the
association rate of 125I-IL-13 varied with the ligand concen-
tration. We performed these experiments using 10 to 500
pM 125I-IL-13. Additionally, in some experiments, we used
two concentrations of target cells, 0.5  106 and 1  106.
FIGURE 2 Dissociation kinetics of IL-13
from IL-13R on control and MLc-RCC
cells. Values represent the averages of dupli-
cate determination. Time-dependence of 125I-
IL-13 dissociation at initial concentrations 15
pM (A, D), 150 pM (B, F) and 200 pM (C, E)
were fitted by the one-exponential model
(solid curves). The SD of mean values was
not larger then 0.06. These experiments were
repeated two times with similar results.
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As shown in Fig. 3, A and B, the slope of the normalized
binding curves increased monotonically with the ligand
concentration in control MLneo cells, but, in contrast, the
slope decreased in c-transfected cells. These results sug-
gest that the binding rate and/or number of available binding
sites in c-negative RCC cells increase with the concentra-
tion of ligand, and c-transfection suppresses the positive
cooperative mechanism of binding of IL-13 to its receptor(s).
Sadana and Beelaram (1996b) successfully applied ki-
netic fractal models to interpret the dependence of binding
rate constants on ligand concentration in biosensor systems.
These models describe the effect of topological complexity
(fractal dimension) of the surfaces that carry the specific
receptor. Surface complexity imposes 1) heterogeneity in
the rate of ligand binding due to the geometric difficulty of
diffusion of ligand to different surface regions, and 2) a
nonuniform distribution of receptor molecules on the sur-
faces. We show that this type of model can be also applied
to the analysis of IL-13 binding on cell surfaces. Figure 3,
A and B shows that Eq. 3 fits well to the initial (transit)
phase of specific IL-13 binding data. The effective rate of
IL-13 binding by the fractal kinetic model, f (f  k1x0),
increased from 0.41  0.01 h1 to a saturation level of
0.58  0.004 h1 in control MLneo cells (Fig. 3 C), but it
was very low (f  0.029  0.007 h
1) and independent of
an initial concentration of IL-13 in the c-transfected cells.
This analysis shows that transfection of c chain reduces the
effective rate of binding, f, by a factor of 20.
The Df, parameter of Eq. 3, is the fractal dimension of the
cell membrane that displays how much space it occupies.
This parameter is a measure of the degree of complexity of
the natural or artificial surfaces, and it also characterizes the
degree of irregularity of the distribution of binding sites on
the surface (Havlin, 1989; Sadana and Beelaram, 1996b).
Figure 3 D shows that Df increases with increasing concen-
trations of IL-13 at low initial concentrations of IL-13.
However, at higher concentrations of ligand, this parameter
did not change. The constant level of Df in control cells was
significantly higher than in c-transfected RCC cells.
Thus, fractal kinetic analysis exhibits an anomalous re-
action order and concentration dependence of the associa-
tion rate coefficient in control c-negative cell line; how-
ever, in c-transfected cells, these effects were not observed.
Analysis of binding/dissociation kinetics by one
receptor model
The effective rate of binding of IL-13, f, is defined as a
product of the association rate constant (k1) and the number
of binding sites R0. The rapid effective rate observed in
MLneo cells, suggests a higher rate of binding or higher
FIGURE 3 Dose-dependence of specific
binding of 125I-IL-13 (specific bound/total
125I-IL-13, z/y0) on MLneo (A) and MLc-
transfected (B) RCC cells, integral rate bind-
ing (C) and fractal dimension parameter (D)
at various ligand concentration. (A) 0.5 
106 cells and 10 pM (——), 15 pM
(—‚—), and 500 pM (—●—) 125I-IL-13;
(B) 106 cells and 15 pM IL-13 (——), 106
cells and 200 pM IL-13 (——), and 0.5 
106 (—ƒ—) 300 pM 125I-IL-13. Kinetic
binding studies were performed as described
in Fig. 1. Bound 125I-IL-13 was plotted as the
ratio of specific bound ligand to the total
radiolabeled ligand after subtraction of the
nonspecifically bound fraction as described
in Materials and Methods. Values represent
the average of duplicate determinations:
SEM values for each point are not shown to
simplify presentation. The values of SD of
the mean were not larger than 0.07. Experi-
ments were repeated two times. The values
of SD smaller than size of the points were
not presented on the figures C and D.
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number of binding sites on the cell surface or both. The
kinetic fractal model described in Eq. 3 did not allow us to
discriminate between these possibilities.
We used association and dissociation measurements at
different initial concentrations of IL-13 to evaluate the
association rate (k1), dissociation rate (k1) and the number
of binding sites per cell. We calculated these parameters
using the simple one-receptor model (Eq. 2). Dissociation
and binding kinetic experiments were performed using the
same experimental protocol. This model fit our binding
kinetics data in both control and c-transfected ML-RCC
cells at each initial concentration of 125I-IL-13, taken sep-
arately to fit the mathematical model. Figure 4 shows the fit
of this model at low (15 pM) IL-13 concentration. The
analysis shows that, following c transfection, the number
of IL-13-specific binding sites on the cell surface was
reduced and the affinity of this binding site decreased.
These differences were defined at different initial concen-
trations of IL-13 and cells. However, we found that the
estimated parameters, k1 and R0, changed monotonically
with ligand concentration in both cell lines (Fig. 5 A and B).
The rate of these changes differed in control and c-trans-
fected cells as a function of ligand concentration. At a low
concentration of IL-13 (10–15 pM), a small number (330–
440 sites per cell) of super-high affinity binding sites (Kd 
k1/k1 0.1 pM) was estimated to exist on MLneo cells, and
a small number (170 sites per cell) of very high affinity
binding sites (Kd  1.4  10 pM) on MLc cells. At higher
concentrations of IL-13, the number of binding sites in-
creased for both RCC cell lines. These alterations of the
number of binding sites and the association rate constant at
various concentrations of ligand with an invariant rate of
dissociation cannot be explained by a one-binding site li-
gand-receptor model.
Analysis of ligand concentration dependence of
binding kinetics with Berg-Pursell model
The Berg-Pursell diffusion limit model (Berg and Pursell,
1977) was successfully used to explain the dependence of
apparent association rate and apparent dissociation rate on
the number of receptor molecules for some ligand-receptor
systems (Erickson et al., 1987; Goldstein et al., 1989; Pos-
ner et al., 1992). According to the Berg-Pursell model, the
ligand diffuses to a smooth spherical cell, closely ap-
proaches the cell surface, and forms a reversible complex
with receptor sites. It was assumed that total concentrations
of receptor and ligand does not change during the process.
If the receptor has one binding site for ligand and the
ligand-receptor complexes are in quasisteady state, then the
apparent association rate coefficient and the apparent dis-
sociation rate coefficient were modeled as
k1 kon/1 Rkon/k, (8)
k1 koff/1 Rkon/k), (9)
R x/Nc R0free x0/Nc1 1 y/y0y0/x0, (10)
where R is the average number of free binding sites on the
cell surface; x, y are the concentrations of free ligand and
free membrane receptor at steady state, respectively; x0, y0
are the initial concentrations of receptor and ligand, respec-
tively; Nc is the number of cells per mL; R0 is the average
number of binding sites per cell; and free is the fraction of
free binding sites (i.e., free  x/x0  1  (y0  y)/x0); kon
and koff are the fundamental rate constants of association
and dissociation; k is the diffusion limited forward rate
constant, and k  4Da, where a is the radius of a cell and
D, is the diffusion coefficient of the ligand.
According to these equations, the effective rate of asso-
ciation must increase, when the initial concentration of
ligand is increased. This is reasonable, because a higher
concentration of ligand reduces the local concentration gra-
dient (i.e., concentration change) of ligand near the cell
surface and leads to the occupation of more receptor mol-
ecules. Furthermore, increasing the ligand concentration
abolishes the diffusion limit. Therefore,
lim
y03
k1y0 kon .
FIGURE 4 Association kinetic data and theoretical curves for 125I-IL-13
binding. 15 pM 125I-IL-13 was incubated with 0.5  106 MLneo and 10
6
c-transfected RCC cells at 4°C. Association kinetics was determined as
described in Material and Methods. Closed circles, MLneo RCC; open
circles, MLc-RCC. Symbols represent the mean values. Theoretical
curves (solid lines) were generated by the model, Eq. 2, after fitting
theoretical curves to experimental points. These curves were calculated at
(1) k1  0.36 (h pM)
1, k1  0.023 h
1, R0  440 sites per cell in the
case of MLneo RCC cells and (2) k1  0.0094 (h pM)
1, k1  0.014 h
1,
R0  170 sites per cell in the case of c-transfected RCC cells. The
amounts of dissociation rate constants, k1, were determined from analysis
of dissociation assay (see Fig. 2).
160 Biophysical Journal Volume 77 July 1999
The parameter, k1, follows the same type of dependence
on y0 as was shown for k1: it must increase with increasing
ligand concentration.
Our observations of dependence of the parameters k1, k1
on the initial ligand concentration disagreed with the pre-
dictions of dose-dependence for these parameters by the
Berg-Pursell model. Figures 2 and 3 shows k1 decreasing
and k1 independent of the initial concentration of IL-13.
This behavior was found for both MLneo and MLc cells.
We also observed the same behavior at much higher con-
centrations of ligand (50–200 pM 125I-IL-13 and 50–100
nM unlabeled IL-13).
Numerical analysis of Eqs. 8–10 shows that the kinetic
parameters kon and k1 are very similar for concentrations of
IL-13 from 10 to 500 pM. For example, for MLneo cells,
when y0 10 pM, D 10
6 (cm2/s), a 4 m; then k 
1.09  104 (pM h)1  5.02  109 (cm3/s)  3  1012
(s M)1; k1  5.3  10
7 (s M)1; free  [1  (0.25 
10)/2.75]  0.089; R  330  free  0.089  330  29
copies/cell; kf R (5 10
7)29 1.5 109. Thus, kon 
5.5  107 (s M)1  k1.
Similar results were obtained for other initial concentra-
tions of IL-13. These results suggest that ligand diffusion
did not limit the binding step of the reaction. Thus, the
diffusion step in two-step binding kinetics (diffusion 
binding of ligand) is negligible for IL-13 binding.
A two-independent receptor model in
c-transfected ML-RCC cells
Because c-transfection abolishes the dependence of IL-
13R binding rate on the concentration of IL-13, and the
dissociation curves demonstrate a very fast and a very slow
phase, it was reasonable to assume that binding, dissocia-
tion, and displacement curves could be described by a
two-independent binding site model (Eq. 4, Tables 1 and 2).
Figure 6 shows that the model by Eq. 4 can fit the binding
and dissociation kinetic curves at different concentrations of
ligand. These results indicate that MLc cells express inter-
mediate-affinity (R10) and high-affinity (R20) binding sites.
R10  3030  2300 copies/cell and R20  560  60
copies/cell. The association rate and dissociation rate con-
stants for the first type of receptor were k1  1.5  10
3
(h pM)1 and k1  5.0  4.0 h
1. The kinetic constants
for the second type of receptor were k2  1.9  10
3 
0.2  103 (h pM)1, and k2  0.015  0.004 h
1. The
parameters were evaluated with the fitting procedure as
FIGURE 5 The 125I-IL-13 concentra-
tion dependence of k1, R0 in the MLneo
(A, B) and MLc (C, D) RCC cells. The
decrease of parameter k1 was fitted to the
exponential model; the increase in a
number of available binding sites, R0, at
IL-13 concentration was fitted to a linear
regression model.
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described in Material and Methods. The dissociation con-
stants for intermediate-affinity and high-affinity receptors
were estimated as K1  k1/k1  3.3 nM and K2 
k2/k2  8 pM. We also investigated the accuracy of the
estimated parameters by fitting the model with displacement
assay data. Figure 6 D shows that our model agrees with the
displacement assay protocol. The numerical values of the
parameters of the model were the same, which was found by
fitting the binding/dissociation kinetic data.
Analysis of potential models of IL-13 binding in
MLneo c-negative cells
We also applied a two-binding site model to simultaneously
fit binding and dissociation kinetic curves on MLneo RCC
cells at different concentrations of radiolabeled ligand.
However, this model did not accurately describe the kinetic
binding experiments at different concentrations of ligand
(data not shown). We also tried to improve fitting by using
an advanced nonsteady-state diffusion-reaction model
(Goldstein and Dembo, 1995). This model took into account
diffusion-controlled binding of ligand to two receptor pop-
ulations and included the possibility of rebinding of ligand
after dissociation from each type of receptor. However, this
model was also rejected by goodness-of-fit statistical
analysis.
Neither a three-independent receptor binding site model
nor a model of homodimerization of IL-13R induced by
ligand binding fit our set of experimental data. We also
modified a two-binding site model so that a fraction of a
receptor could bind to more than one IL-13 molecule. How-
ever, the goodness of fit analysis revealed a poor fit of this
model (data not shown).
A model of ligand-induced coreceptor mediated
binding in MLneo RCC cells
Because neither simple one-site model or other conven-
tional models adequately fit the set of binding and dissoci-
ation data, a cooperative binding model was tried. We
postulated that the association rate is a nonlinear function of
free ligand concentration, so that the binding rate is in-
creased (or decreased) over time while binding occurs. We
also proposed that a third molecule, dubbed the coreceptor
TABLE 1 Equations for mathematical models of IL-13 and IL-13 receptor interactions for ML-RCC cells without and with c-
chain expression
Control Cells c-Expressed Cells
Binding Assay
dzt/dt  n1ybyx  n1z  dzct/dt dz1t/dt  k1x1y  k1z1
dzct/dt  n2zc  n2zc dz2t/dt  k2x2y  k2z2
dit/dt  n4zc  dyit/dt
dyit/dt  n3iy  n3yi
xt  x0  zt  zct x1t  x10  z1t
ct  c0  zct x2t  x20  z2t
yt  y0  zt  zct  yit yt  y0  z1t  z2t
Act  zt  zct/y0 At  z1t  z2t/y0
Dissociation Assay
dzt/dt  n1z  dzct/dt dz1t/dt  k1z1
dzct/dt  n2zc  n2zc dz2t/dt  k2z2
ct  c0  zct
Bct  zt  zct/z  zc Bt  z1t  z2t/z1  z2
Displacement Assay
dzt/dt  n1ybyx  n1z  dzct/dt dz1t/dt  k1x1y  k1z1
dqt/dt  n1y1
by1x  n1q  dqct/dt dq1t/dt  k1x1y1  k1zq1
dzct/dt  n2zc  n2zc dz2t/dt  k2x2y  k2z2
dqct/dt  n2qc  n2qc dq2t/dt  k2x2y1  k2q2
dit/dt  n4zc  qc  dyit/dt  dy1i/dt
dyit/dt  n3iy  n3yi
dy1it/dt  n3iy1  n3y1i
xt  x0  zt  zct  qt  qct x1t  x10  z1t  q1t
ct  c0  zct  qct x2t  x20  z2t  q2t
yt  y0  zt  zct  yit yt  y0  z1t  z2t
y1t  y10  qt  qct  y1it y1t  y10  q1t  q2t
Cct  zt  zct/zt  zct Ct  z1t  z2t/z1t  z2t
Internalization Assay
dzft/dt  1zf  inzf
dzst/dt  2zs
dzoutt/dt  1zf  2zs
dzint/dt  inzf
Cst  zft  zst/zf  zs;
Cint  zint/zf  zs; Coutt  zoutt/zf  zs
(See definitions in Table 2).
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TABLE 2 Definitions and typical units of all variables and parameters of this work
Symbol Definition Units
x Unbound cell surface receptor molecules concentration nM
y Free ligand molecules concentration nM
z Cell surface ligand–receptor complexes concentration nM
c Unbound cell surface coreceptor molecules concentration nM
zc Cell surface ligand–receptor–coreceptor complexes concentration nM
y1 Free (unlabeled) ligand-competitor complexes concentration nM
i Free inhibitor molecules concentration nM
yi Ligand–inhibitor complexes concentration nM
y1i Ligand-competitor–inhibitor complexes concentration nM
q Cell surface ligand-competitor–receptor complexes concentration nM
qc Cell surface ligand-competitor–receptor–co-receptor complexes concentration nM
y0 Initial ligand molecules concentration nM
x0 Initial cell surface receptor molecules concentration nM
z0 Initial cell surface ligand–receptor complexes concentration nM
c0 Initial cell surface coreceptor molecules concentration nM
zc0 Initial cell surface ligand–receptor–coreceptor complexes concentration nM
y10 Initial (unlabeled) ligand-competitor concentration nM
i0 Initial free inhibitor molecules concentration nM
yi0 Initial ligand–inhibitor complexes concentration nM
y1i0 Initial ligand-competitor–inhibitor complexes concentration nM
q0 Initial cell surface ligand-competitor–receptor complexes concentration nM
qc0 Initial cell surface ligand-competitor–receptor–coreceptor complexes concentration nM
y10 Initial ligand-competitor complexes concentration nM
Ac A fraction of bound ligand (observed variable) in binding assay none
Bc A fraction of bound ligand (observed variable) in dissociation assay none
Cc A fraction of bound ligand (observed variable) in displacement assays none
z  zc, z1  z2 Bound ligand concentration at the absence of ligand-competitor (i.e., at y10  0) nM
x1 Concentration of the unbound cell surface copies of the type 1 receptor nM
x2 Concentration of the unbound cell surface copies of the type 2 receptor nM
z1 Cell surface ligand–receptor type 1 complex concentration nM
z2 Cell surface ligand–receptor type 2 complex concentration nM
q1 Cell surface ligand-competitor–receptor type 1 complex concentration nM
q2 Cell surface ligand-competitor–receptor type 2 complex concentration nM
x10 Initial concentration of the cell surface type 1 receptor molecules nM
x20 Initial concentration of the cell surface type 2 receptor molecules nM
z10 Initial cell surface ligand–receptor type 1 complex concentration nM
z20 Initial cell surface ligand–receptor type 2 complex concentration nM
q10 Initial cell surface ligand-competitor–receptor type 1 complex concentration nM
q20 Initial cell surface ligand-competitor–receptor type 2 complex concentration nM
zf Unbound cell surface fast receptor molecules concentration nM
zs Unbound cell surface slow receptor molecules concentration nM
zin Internalized ligand–receptor complex molecules concentration nM
zout Shed/dissociated ligand molecules concentration nM
 Initial time point of dissociation assay or internalization assay min
A Fraction of bound ligand (the observed variables) in binding assay none
B Fraction of bound ligand (the observed variables) in dissociation assay none
C Fraction of bound ligand (the observed variables) in displacement assays none
Cs Fraction of cell surface bound ligand in internalization assay none
Cin Fraction of internalized ligand none
Cs Fraction of shed/dissociated ligand in internalization assay none
t Time h
Nc Concentration of cells M
1
R0 Total number of binding sites per cell #/cell
R Total number of free binding sites per cell #/cell
NR Number of receptor molecules per cell #/cell
NC0 Number of coreceptors molecules per cell #/cell
R1 Number of type 1 receptor molecules per cell #/cell
R2 Number of type 2 receptor molecules per cell #/cell
D Diffusion coefficient cm2/s
Df Fractal dimension constant of cell surface none
f Effective binding rate h
1
k1 Rate constant for association of ligand–receptor complexes [h pM]
1
k1 Rate constant for dissociation of ligand–receptor complexes h
1
k2 Rate constant for association of ligand–receptor complexes [h pM]
1
k2 Rate constant for dissociation of ligand–receptor complexes h
1
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subunit, exists and helps keep the ligand on the cell surface
for a long period of time and causes the release of the
inhibitor molecule(s). This inhibitor molecule drifts away
from the cell membrane and binds to free IL-13 molecules
in the medium, which are then captured so they cannot bind
to receptors on the cell membrane. This last assumption is
consistent with the fact that both small and large concen-
trations of IL-13 appear to have almost the same binding
effect at the steady-state phase of reaction (Fig. 7 A and B).
Based on these assumptions, we established the following
model for IL-13 binding on the cell surface.
x yº
n1
n1yb
z, (11)
z cº
n2
n2
zcO¡
n4
zc i, (12)
y iº
n3
n3
yi, (13)
where y, x, and c are the free (unbound) ligand (IL-13), free
primary binding subunit, and free coreceptor, respectively; i
is the inhibitor (released or shed from cell surface mole-
cules); z and zc are the complex (x y) and three-molecular
complex (c  x  y); yi is the inactivated ligand, i.e., the
(y  i) complex. n1 and n1 are the association and disso-
ciation constant rates of IL-13 to the primary binding sub-
unit; n2 and n2 are the association and dissociation rate
constants of the IL-13 bound primary receptor to the free
coreceptor, respectively; n3 and n3 are the association and
dissociation rates of the inhibitor to IL-13; and n4 is the rate
of release/shedding of the inhibitor from cells to medium.
A small but significant amount of cooperativity is present
in reaction 11 (see also Fig. 3). This is modeled by assuming
that the association constant for this reaction is of the form
n1y
b with 0  b 	 1, where b is the cooperative binding
parameter of IL-13R expressed on the cell membrane. This
parameter indicates the level of heterogeneity of binding
capacity of binding sites on cell surfaces that can be corre-
lated to the complexity (fractal dimension) of the cell sur-
face. The complex shape of a cell membrane can impose a
restraint on the binding of ligand to receptor molecules
localized in inaccessible regions. The parameter b could
also indicate the fraction of binding sites that pre-exist on
the cell membrane in a homodimer and/or heterodimer form
in the absence of external ligand. If b  0, then the binding
kinetics follows the classical mass laws kinetic reactions, if
b 
 0, then positive cooperativity in binding is expressed.
Table 1 contains a mathematical model of binding assays
for IL-13–IL-13R interaction in control RCC cells. Note
that, for the binding kinetic model, the constant y0 is the
initial concentration of ligand (pM), and x0 (pM), and c0
(pM) are the concentrations of primary binding sites and
coreceptor copies, respectively, z(0)  zc(0)  yi(0) 
i(0)  0.
By fitting differential equations for reactions 11–13 to
our set of binding and dissociation data (Fig. 7) at different
initial concentrations of IL-13, we estimated the set of
constants x0, c0, n1, n1, n2, n2, n3, n3, n4, and b. The
average number of binding sites and average number of
coreceptor copies per cell was evaluated by Eqs. NR x0/Nc
and NC0  c0/Nc, where Nc is the concentration of target
cells. When we applied the fitting procedure, we found high
correlations between estimated values x0, and c0, as well as
between a few other estimated parameters. In other words,
the available experimental data allowed estimation of the
TABLE 2 Continued
Symbol Definition Units
n1 Rate constant for association of ligand–receptor complexes [h pM]
1
n1 Rate constant for dissociation of ligand–receptor complexes h
1
n2 Rate constant for association of ligand–receptor complex with coreceptor [h pM]
1
n2 Rate constant for dissociation of ligand–receptor complexes and coreceptor h
1
n3 Rate constant for association of ligand–inhibitor complexes [h pM]
1
n3 Rate constant for dissociation of ligand–inhibitor complexes h
1
n4 Rate constant for release of inhibitor molecules by cells [h pM]
1
kon Fundamental rate constant for binding [h pM]
1
koff Fundamental rate constant for dissociation h
1
k Diffusion limited forward rate constant [h pM]
1
1 Constant rate for shedding/dissociation of ligand–receptor type 1 complexes h
1
2 Constant rate for shedding/dissociation of ligand–receptor type 2 complexes h
1
in Constant rate for internalization of ligand–receptor type 1 complexes h
1
in Constant rate for internalization of ligand–receptor type 2 complexes h
1
a Radius of a cell m
b Cooperative binding parameter none
Kd Equilibrium dissociation constant nM
NA The Avogadro number ( 6.02  10
23) #/mole
t1/2 Half-time h
free Fraction of free binding sites none
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ratio of these parameters but not their values individually.
This parametrization property often limits the predictive
power of kinetic models. Therefore, to reduce the number of
calculated parameters and their correlations, we fixed a
mean of parameters x0, n1, n2, and n3. The number of
binding sites per cell, R0 (R0  x0/Nc or concentration of
IL-13 receptor (x0)), on the control MLneo cells have been
previously evaluated using a one-receptor model (Obiri et
al., 1996b). This number varied from 360  103 to 620 
103 molecules/cell. We assumed that NR  360  10
3
molecules/cell. The constant, n1, was estimated by fitting
the two-binding site model (see Eq. 6) to the set of disso-
ciation curves. The amount of rate constants n3 (n3  4
(h pM)1) and n2(n2  1.22  10
4 (h pM)1) were taken
from the best set of constants when we applied the fitting
procedure for evaluation of complete set of constants, i.e.,
x0, c0, n1, n1, n2, n2, n3, n3, n4, and b. Finally, we
simultaneously estimated 6 constants: c0, n1, n2, n3, n4,
and b, using about 60 duplicate experimental points of 7
kinetic curves.
Figure 7 shows the result of fitting of the mathematical
model for reactions 11–13 using the best set of parameters:
c0  5587  222 pM (or NC0  336  10
3  14  103
molecules/cell); n1 3.36 0.25 10
4 (h pM)1; n1
4.8 h1; n2 1.22 10
4 (h pM)1; n2 0.023 0.001
h1; n3  0.23  1.55 h
1; n3  4  8 (h pM)
1; n4 
0.83  0.05 h1; b  0.09  0.015.
These results show that a large number of coreceptor
molecules are expressed on the cell surface of control MLneo
cells. The effective rate of ligand association to primary
receptor (n1x0 2.0 h
1) is 3 times higher than the effective
rate of capture of ligand-receptor complexes by coreceptor
(n2c0  0.68 h
1). The dissociation constant of the primary
receptor, coreceptor, and inhibitor complexes differed dra-
FIGURE 6 Fitting of two-independent receptor model. Association of IL-13 to the surface receptors (A, B), dissociation of IL-13 (C) from the cell
membrane, and a numerical prediction of displacement curve (D) in the MLc RCC is shown. The initial conditions were: (A) y0 15 pM, Nc 10
6 cell/mL
(--); y0  200 pM, Nc  1.0  10
6 cell/mL (––), y0  300 pM, Nc  1  10
6 cell/mL (--e--); (B) y0  150 pM, Nc  0.5  10
6 cells/mL (--‚--),
y0  200 pM, Nc  0.5  10
6 cells/mL (----), (C) y0  15 pM, Nc  10
6 cell/mL (--E--); y0  150 pM, Nc  0.5  10
6 cell/mL (--‚--); y0  200
pM, Nc  0.5  10
6 cell/mL (----); y0  200 pM, Nc  10
6 cell/mL (––);   4 h (D) Displacement assays were performed in separate experiments,
106 cell MLneo cells were incubated with 100 pM
125I-IL-13 in the absence or presence of different concentrations of unlabeled IL-13 (from 5 pM to 110
nM) at 3.5 h. The lines show theoretical curves.
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matically: KdR  n1/n1  14.3 nM, KdC0  n2/n2  188
pM, Kdi  n3/n3  0.06 pM, respectively.
IL-13 displacement analysis in MLneo cells
Because our model suggested a new control mechanism
mediated by the postulated coreceptor component, it was
important to determine if our model was accurate, and if the
parameter estimations were stable over a broad range of
IL-13 concentrations. We designed binding and displace-
ment assays simultaneously in the same experimental pro-
tocol (Fig. 8). We used 50 pM 125I-IL-13, and the concen-
tration of unlabeled IL-13 was varied from 5 pM to 200 nM.
The model for the displacement assay was constructed from
Eqs. 11–13 for radiolabeled ligand binding and by the
schema
x y1º
n1
n1y1
b
q, (14)
z cº
n2
n2
qcO¡
n4
qc i, (15)
y1 iº
n3
n3
y1i, (16)
for unlabeled IL-13 binding. Where y1 is free (unbound)
unlabeled IL-13; q and qc are the complex (x  y1) and
three-molecular complex (c  x  y1); i is the inhibitor
produced after binding of the coreceptor with ligand-recep-
tor complex q; y1i denotes inactivated unlabeled ligand.
Corresponding mathematical model is presented in Table 1.
The five relatively sensitive parameters n1, n2, n3, n4, and
b were estimated along with fixed parameters (n1  4.8
h1, n2 0.023 h
1, n3 0.23 h
1, x0 5980 pM, c0
5587 pM) by fitting the binding and displacement assays.
The result of simultaneously fitting the model for the bind-
ing/dissociation reactions described in Eqs. 11–13 (Fig. 8 A)
FIGURE 7 (A, B) 125I-IL-13 binding kinetics, (C) dissociation kinetics, and (D) simulation of time course of separate variables of mathematical model.
Kinetics of binding experimenters were performed at various initial concentrations of radiolabeled IL-13 such as (A) y01  15 pM (), y02  500 pM ().
(B) y03  70 pM (‚), y04  200 pM (). (C) Dissociation experiments were performed at y05  15 pM, (), y06  200 pM (), y07  500 pM ()  
5 h. The values of SD and mean were not larger than 0.07. Kinetic binding and dissociation studies were performed as described in Figs. 1 and 2. The lines
are the theoretical kinetic curves. Kinetics of the ligand receptor complex (z  [x  y]) (solid line), three-molecular complex (zc  [y  x  c0]) (dash
line) and inhibitor (i) (dot line) are shown at the initial conditions: (D) y0  15 pM; x0  5980 pM, c0  5587 pM; z  zc  yi  i  0.
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and the model for the displacement reactions Eqs. 11–16
(Fig. 8 B) demonstrates that our model agrees with these
sets of observations. A mathematical model for Eqs. 11–13,
and 14–16 fits data using parameters that are very similar to
parameters described in Fig. 7.
Thus, we can conclude that our stoichiometric model,
11–13, can describe IL-13–IL-13R binding on cells that do
not express c, at least for concentrations of IL-13 from 10
pM to 200 nM.
Internalization of 125I-IL-13
As shown in Fig. 9, the rate of internalization and dissoci-
ation/shedding of IL-13 at 37°C was higher for control cells.
However, the relative distribution of 125I-IL-13 on the cell
surface, within cells, and in the medium were similar. Sim-
ilar internalization and dissociation/shedding was observed
for another RCC cell line (HL-RCC). Figure 10 shows the
kinetics of 125I-IL-13 binding on the cell surface, fraction
remaining inside the cell, and unbound radiolabeled IL-13
in the cell culture medium for HL, MLneo, and MLc-
transfected RCC cell lines. Kinetic data are shown after
normalization. IL-13 internalization kinetics in all types of
cell lines was similar. The solid lines show the numerical
solutions according to the two-state receptor model
FIGURE 8 125I-IL-13 association and displacement assays. The associ-
ation kinetic experiments were performed using 50 pM 125I-IL-13 and
0.5  106 MLneo cells. (A) Displacement assays were performed using 85
pM 125I-IL-13, 1  106 MLneo cells and various concentrations of unla-
beled IL-13 (from 5 pM to 200 nM) for 2.7 h incubation at 4°C. (B) The
numerical solutions were derived from the model, Eqs. 11–13, (A), 14–16
and are shown by solid lines. The values of SD of the mean were not larger
than 0.07.
FIGURE 9 IL-13R-mediated dissociation/shedding and internalization
of 125I-IL-13. Control (filled symbols) and c transfected (open symbols)
ML-RCC cells (2.4  106) were preincubated for 5 min in binding buffer
containing 0.2 nM chloroquine at 37°C and then incubated in the same
volume with 300 pM 125I-IL-13 for 3.5 hr at 4°C. Cells were washed two
times and the temperature was then raised to 37°C. At various time
intervals, two duplicate sets of 50 L aliquots were taken. One set was
incubated with glycine buffer (final pH  2.0) for 10 min. The suspension
was then centrifuged through a mixture of phthalate oils and the radioac-
tivity in the supernatant (A, surface bound  dissociated) and in the cell
pellet (C, acid resistant or internalized) was determined with a gamma
counter. The other set of 50 L aliquots (B) was directly centrifuged
through phthalate oils and the radioactivity observed in the supernatant was
used for dissociated 125I-IL-13 values.
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(Kuznetsov, 1990; Kuznetsov and Borisova, 1995b). Only
15–25% and 12–17% of total bound radiolabeled ligand is
internalized by control and c-transfected RCC cells, re-
spectively. The same fractions were dissociated or shed
from cell surfaces. Internalization in these cell lines was
ceased after 20–45 min. After this period, a fraction of
internalized ligand stayed at the steady-state level within the
cell for at least 4.5 hours. These results indicate that two
types of IL-13R or conformation states of single IL-13R
might exist on the surface of HL, MLneo, and c-transfected
RCC cells, which differ in their rate of internalization and
dissociation/shedding. The two-state receptor model, Eq. 4
[but not the one-state receptor model (data not shown)],
provided the best fit for all experimental data (Fig. 10). The
estimations of the kinetic parameter values 1, 2, in, out,
and the ratio between fast and slow forms of IL-13R at
quasisteady state of binding, zf0/(zf0  zs0), are listed in
Table 3. These data indicate that c does not affect IL-13
internalization, but that it accelerates the shedding/dissoci-
ation of the fast form of IL-13R in RCC cells compared to
c-negative control RCC cells. In addition, the ratio be-
tween fast and slow forms of IL-13R at quasisteady state of
binding is unchanged by c-transfection.
Table 1 summarizes the models for IL-13–IL-13R inter-
action in cells without and with c-expression. In the table,
we included the functions A(t), Ac(t), B(t), Bc(t), C(t), Cc(t),
Cs(t), Cin(t), Cout, which were used for fitting of the models
to experimental data. Table 2 contains the definitions and
dimension of the variables and parameters of our models.
Effect of c expression on growth kinetics of
RCC cells
To assess the physiological significance of expression of c,
we compared the growth of control and MLc-transfected
cells. Figure 11 shows that growth rate of MLc-transfected
cells is about two times higher than the growth rate of
negative control MLneo cells. Thus, reducing IL-13R ex-
pression on transfected cells correlates with enhancement of
RCC growth.
DISCUSSION
This is the first report describing the kinetics of binding,
dissociation, and internalization of IL-13 after binding to its
receptors. We describe a new phenomenon associated with
the IL-13 receptor where the apparent rate of association,
but not dissociation, is strongly related to IL-13 concentra-
tion. The dissociation curves show both a fast and a very
slow decay phase. Binding and dissociation assays indicate
that IL-13R exists in both high-affinity (Kd  188 pM) and
intermediate-affinity (Kd  14 nM) forms on MLneo RCC
cells and in very high affinity (Kd 8 pM) and intermediate
affinity (Kd  3.3 nM) forms on c-transfected cells. These
data agree with displacement assays using unlabeled ligand
as a competitor. Our results lead to the assumption that the
dominant kinetic mechanism for IL-13R may depend on the
initial concentration of ligand, and on topological and phys-
ical properties of the cell membrane.
FIGURE 10 Endocytosis and dissociation/shedding of surface bound
125I-IL-13 by RCC cells. (A) HL, (B) MLneo, and (C) MLc cells (1.8 
106) were processed and incubated as described in Fig. 9. Fractions of
specific surface-bound (–F–), internalized (–f–) and shed/dissociated
ligand (–Œ–) were calculated by the formula presented in Materials and
Methods. Kinetic parameter values are listed in the Table 3. The results
were reproduced in two separate experiments.
TABLE 3 Parameters and estimates for internalization/
dissociation of 125I-IL-13
Cell
Lines
in
(h1)
in
(h1)
1
(h1)
2
(h1) zf
0/(zf
0  zs
0)
HL 1.74 0.00 2.9 0.096 0.41
MLneo 1.50 0.00 0.78 0.072 0.32
ML 1.26 0.00 2.22 0.084 0.30
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We demonstrate that the kinetics of IL-13R binding on
ML-RCC cells cannot be explained by a one-receptor
model. A two-independent receptor model fit our data for
MLc-transfected cells (Fig. 6), but this model (and its
modifications) did not fit for MLneo RCC cells. Further-
more, we observed time-dependence of association rate
constants for control MLneo RCC cells. Binding, dissocia-
tion, and displacement experiments do not quantitatively
follow common classical ligand-receptor models and were
rejected with statistical goodness-of-fit analysis.
When we applied a one-receptor model, then the apparent
rate of binding and the number of IL-13 binding sites
depended upon the initial ligand concentration (Figs. 4 and
5). This phenomenon has not been reported previously for
any interleukin receptors. Dependence of a binding rate
constant on ligand concentration has been well established
for molecular-surface interactions for several ligand-recep-
tor systems (Franco et al., 1996; Sadana and Beelaram,
1996a,b). The high fractal dimension of control RCC cell
surfaces in comparison with c-transfected RCC cells is
consistent with our light microscopic observations in that
MLc cells exhibit some morphological differences. The
MLc RCC cells appear about 65% smaller, more elon-
gated, and smoother than the MLneo RCC cells (data not
shown). We estimated that the fractal dimension of the
surface of control cells (MLneo) is significantly higher (Df
2.4) than the fractal dimension of the surface of c-trans-
fected RCC cells (Df  1.9) (Fig. 3 D). Our estimation of
the fractal dimension Df for ML-RCC cells correlates with
digital image analysis data of membrane profiles of other
tumor cells that have shown morphological complexity and
high fractal dimension (Keough et al., 1991; Nonnenmacher
et al., 1994). Thus, the kinetic anomalies observed in our
system may be explained by the effects of nonuniform
distribution of receptor molecules in different domains of
the cell surface. The cell surface complexity may provide
more favorable physical conditions for accumulation of the
receptor molecules on some domains and for receptor clus-
terization in these domains. In contrast, local complexity of
the landscape of the cell surface may provide physical
constrains for diffusion of IL-13 molecules and its interac-
tion with the receptors in some surface domains. Based on
fractal kinetic analysis, we assume that a small fraction of
IL-13 receptor molecules pre-exists as microclusters (at
least, as dimers) (Fig. 12). Because modulation effects of
surface complexity on association rate of IL-13 appears to
be a nonspecific for IL-13 binding, we predict that a similar
cooperative effect in ligand binding may exist for other
types of receptors expressed on MLneo cells.
We have developed a stoichiometric model for IL-13
interaction with its receptors expressed on RCC cells. The
conceptual schema of our model draws on Fig. 12. Accord-
ing to this model, the IL-13R(2) chain binds IL-13 with
high affinity. Referred to the recent data (Donaldson et al.,
1998; Puri et al., unpublished data), we proposed that high
affinity IL-13 R alone may bind IL-13. Furthermore, ML-
RCC cells express coreceptor molecules, which enhance the
association rate binding of IL-13. This coreceptor molecule
stabilizes ligand on the cell surface for a long period of time
causing release of inhibitor molecule(s). Our model predicts
the expression of a large number of the primary IL-13
receptors (360  103 copies per cell) and the coreceptor
molecules (about 340  103 copies per cell) on the cell
surface. The identify of this coreceptor molecule is not
known. The IL-4 receptor  chain forms a complex with
IL-13R, it is possible that the  chain works as a core-
ceptor molecule. However, expression of this chain on the
cell surface of ML-RCC cells is more limited than is the
IL-13 chain (Caput et al., 1996; Obiri et al., 1996b). It is
possible that the IL-13 chain molecule is a candidate for
a coreceptor in our model. IL-13R chain alone binds
IL-13 with a much lower affinity than does IL-13R (Mu-
rata et al., 1998), however,  chain forms a high affinity
IL-13R complex with IL-14 chain. Because the inhibitor-
ligand complex is assumed to be unable to bind to primary
receptors R1 and R2 (Fig. 12; R1 is the IL-13 receptor and
R2 is the heterodimer IL-13–IL-4), the IL-13 binding to
the cell is self-regulated. Recently, the soluble form of the
high-affinity IL-13 binding protein (IL-13BP) has been
detected in the serum and urine of mice (Zhang et al., 1997).
This protein binds IL-13 with a 100–300-fold higher affin-
ity than does cloned IL-13R. A soluble form of IL-13R
chain was also detected in the supernatant of activated
peripheral blood T cells (Graber et al., 1998). These find-
ings, together with predictions of our model, allow us to
propose that, in human ML-RCC cells, IL-13 binding can
induce shedding of a high-affinity soluble form(s) or frag-
FIGURE 11 Effect of c-transfection on kinetics of RCC growth. 35,000
MLneo cells (—F—) or MLc cells (—E—) were cultured in duplicate
Petri dishes for different periods of time as described in Material and
Methods. The exponential model of cell growth fit to experimental data for
MLneo cells and MLc cells at doubling times   64 h, and   30 h,
respectively.
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ment(s) of IL-13R, which should be an effective inhibitor of
biological activities of IL-13. Further studies will examine
these and other possibilities of self-regulatory mechanisms
of activity of the IL-13R complex.
Our conceptual model of IL-13 binding to control cells
(Fig. 12) was not rejected by a goodness-of-fit analysis
(Figs. 7 and 8) and agreed with the literature. Moreover, this
model provided an explanation of two-phase dissociation
kinetics of ligand from the cell surface. Additionally, it
demonstrates the independence of the bound fraction of
IL-13 at the steady state from the initial concentration of
IL-13. Furthermore, our model of IL-13 binding in c-
transfected cells predicted that during the early phase of
IL-13 binding, intermediate-affinity binding sites were oc-
cupied, whereas, at the steady state, very high-affinity bind-
ing sites dominated (Fig. 6 D).
The decrease in IL-13 binding upon c-transfection in
ML-RCC cells, described here, agrees with our previous
report (Obiri et al., 1996b). However, the molecular mech-
anism and the significance of this decrease in IL-13 binding
is still not known. Because IL-13R mRNA was not de-
tected in MLc-transfected cells (Obiri et al., 1996b), it is
reasonable to assume that c-transfected cells did not ex-
press the IL-13 chain on the cell membrane. The expres-
sion of IL-13 mRNA in MLc cells was approximately
three times less than that of control cells (Obiri et al.,
1996b). Because genes encoding c and IL-13R are lo-
calized in the close region of the X chromosome, it is
possible that the expression of c gene suppresses the ex-
pression of IL-13R gene. These predictions are repre-
sented in our model in Fig. 12. According to this model,
c-transfected cells are shown to lack the IL-13R chain
and have a dramatically decreased expression level of the
IL-13R chain.
The increase in the association rate of IL-13 binding
correlates with expression of c chain. The explanation for
this is not clear, but may be related to a stabilizing effect of
c on the IL-13–IL-13R interaction. This effect is well
documented for the IL-2R complex (Matsuoka et al., 1993;
Chang et al., 1996; Borisova and Kuznetsov, 1996). It is
possible that over-expression of c masks the binding site of
moderate affinity IL-13R by steric hinderance inhibiting
IL-13 binding. It is also possible that the over-expression of
c-chain on cell membranes allosterically alters the confor-
mation of the IL-13 receptor complex resulting in a de-
creased number of binding sites and affinity. Further studies
are necessary to define the exact mechanism of these
interactions.
This is the first report demonstrating IL-13 induced re-
ceptor-mediated internalization. We show that only 14–
24% of the surface bound ligand-receptor complexes were
rapidly internalized (within 15–40 min), and similar frac-
tions are dissociated in both control and c-transfected cells.
The majority of radiolabeled receptor complex (60–70%)
remained on the cell surface, and this was unchanged for up
to 5 h of incubation. These data suggest that IL-13R exists
in two different forms on RCC cells (or steady-state con-
formation states); one form is internalized and the other is
noninternalized. These two forms of IL-13–IL13R complex
are distinguishable on the cell surface for up to 40 min of
ligand processing at 37°C.
Interestingly, expression of c gene decreased the number
of binding sites for IL-13, reduced the dissociation rate
constants of IL-13R, and increased the association rate
constants, but it did not modify the steady-state ratio be-
tween the amounts of internalized and noninternalized
FIGURE 12 Proposed model for IL-13 interaction with its receptors on
RCC cells (1) without and (2) with expression of IL-2 c-chain. IL-13 has
been shown to bind low-affinity and high-affinity 70 kDa proteins
termed IL-13R1() and IL-13R2(), respectively. A relatively small
fraction of IL-4 receptor , but no c-chain were also observed on RCC
cells. IL-13R are naturally highly expressed on RCC cells. We assume that
the vast majority of IL-13Rs express only a single binding site; the IL-4
receptor  chain forms dimer with  chain. It is believed that the –
heterodimer pre-exist on the cell membrane of RCC cells before interaction
with the IL-13 molecule, and the number of copies of this receptor complex
depends on the level of morphological complexity (fractality) of the cell
membrane. In the first model, IL-13 binds initially to high-affinity recep-
tors  and –, then the ligand–-receptor complex interacts with the
coreceptor molecule (). Binding IL-13 to – heterodimer explains a
positive cooperativity in kinetics of 125I-IL-13 binding. Release of inhibitor
molecule(s) (I) is mediated by the trimeric IL-13–IL-13– complex. The
extracellular domain of  (and/or ) chain can be cleaved and shed. This
domain can reduce further binding of IL-13 to membrane forms of IL-
13Rs. Binding and dissociation processes, interconversion of complex
states and internalization of ligand-receptor complex are shown by arrows.
The thickness of the arrows schematically indicates the rate of the process.
In the second model, expression of c chain in cell prevents the expression
of  chain molecules and partially reduces expression of  chain. Symbol
X implies inhibition of mRNA transcription of these proteins. Because c
forms a functional complex with IL-4R chain and  chain has stronger
affinity to c than to IL-13R,  chain can rebind to c, and the number
of high-affinity binding sites for IL-13 will be reduced. Because only 
chain has a long intracellular tail, we propose that only IL-13––
complex can be internalized. Thus, both our models demonstrate that the
internalization of ligand-receptor complex is mediated by fast and high-
affinity – receptor complex.
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forms of IL-13R. It also did not change the rate of receptor-
mediated internalization of IL-13 (Fig. 10, Table 3). These
data suggest that, in c-transfected cells, the mechanism of
receptor-mediated endocytosis of IL-13 remains intact. But
c transfection exerts a profound effect on the relationship
between the different types of IL-13 receptor subunits and
its binding activity. The structural and kinetic changes pre-
sented here correlate with changes in signal transduction
pathways of IL-13 (Obiri et al., 1996a, 1997) and a faster
proliferation of MLc-transfected cells compared to control
RCC cells.
In conclusion, we have demonstrated that, for the IL-13R
system, the apparent rate of binding, but not dissociation,
depends upon ligand concentration. These observations pro-
vide a basis for a new theoretical model for membrane
organization of IL-13R and indicate that the traditional
experimental design for the determination of receptor num-
ber and affinity of IL-13R needs to be carefully examined.
We also demonstrated that IL-13 receptors are heteroge-
neous in binding and physiological processes. A fraction of
IL-13R(s) is rapidly internalized after binding to the ligand,
another fraction of bound receptor stays on the cell surface
for many hours. These observations may help explain, at
least in part, the very potent cytotoxic effect of IL-13 toxin
on RCC cells that express IL-13R (Puri et al., 1996a) and
the growth inhibitory effect of IL-13 at low concentration of
IL-13 (Obiri et al. 1996a). Further analysis of these corre-
lations should be developed based on the structure-kinetic
approach presented here.
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